Liaoning Chengda Biotechnology Co. Ltd. A (688739) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Liaoning Chengda Biotechnology Co. Ltd. A ¥11.59, price ¥20.92, upside -44.6%, quality 54 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Liaoning Chengda Biotechnology Co. Ltd. A for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.
How to read this chart
59‑month range ¥19.13 – ¥72.06 · fair‑value band ¥11.30 – ¥11.59 · the ¥20.92 price screens above the ¥11.59 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 23, 2026.
Follow Liaoning Chengda Biotechnology Co. Ltd. A in your weekly email
Every Wednesday you see whether Liaoning Chengda Biotechnology Co. Ltd. A is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Liaoning Chengda Biotechnology Co.,Ltd. a biotechnology company, engages in the research and development, production, and sales of vaccines for human use worldwide. It offers inactivated Japanese encephalitis vaccine (IJEV) and SPEEDA-rabies vaccine.
Show more
Liaoning Chengda Biotechnology Co.,Ltd. a biotechnology company, engages in the research and development, production, and sales of vaccines for human use worldwide. It offers inactivated Japanese encephalitis vaccine (IJEV) and SPEEDA-rabies vaccine. The company's rabies and influenza vaccines are in the new drug application stage; haemophilus influenzae type b vaccine in phase III; recombinant human papillomavirus 15-valent vaccine is in phase II; and 13-valent pneumococcal polysaccharide conjugate and varicella, as well as the live meningococcal A, C, Y and W-135 conjugate vaccine are in phase I. Its Serogroup B meningococcal outer membrane vesicle, 20-valent pneumococcal polysaccharide conjugate, recombinant zoster vaccine, multivalent HFMD (hand foot and mouth disease), high-dose influenza, and inactivated rabies monoclonal antibody vaccine are in the pre-clinical stage. Liaoning Chengda Biotechnology Co.,Ltd. was founded in 2002 and is headquartered in Shenyang, China. Liaoning Chengda Biotechnology Co.,Ltd. is a subsidiary of Liaoning Cheng Da Co., Ltd.
Stock analysis
Liaoning Chengda Biotechnology Co. Ltd. A (688739) currently trades at ¥20.92, while our model-based Fair Value estimate is ¥11.59, implying the stock looks roughly 80.5% overvalued today.
Show more
Valuation
Bull case: the Asset-Based group reads highest at a median of ¥15.05 per share, and 1 of the 24 models we run sit above the ¥20.92 price.
Bear case: the Earnings-Based group reads lowest at ¥2.63, and 23 of the 24 models stay below the price. Evidence for this calculation is high.
Scenario range: ¥11.30 (bear) to ¥11.59 (bull), the price of ¥20.92 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 54/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Liaoning Chengda Biotechnology Co. Ltd. A reported revenue of 1.4B CNY in FY2025 versus 2.1B CNY in FY2021, a compound −9.7%/yr. Reported net income was 132M CNY in FY2025, compounding −38.0%/yr from FY2021.
Key figures
Market cap 8.7B CNY (≈ $1.3B) · P/E ratio 149.4 · P/S ratio 14.2 · EPS (TTM) ¥0.1400 · Dividend yield 0.5% · Net margin 9.5% · Return on equity 0.6% · Return on assets (EBIT) 6.1%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).
What moves the price
The share trades about 25% below its 52-week high and 9% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −45%, 688739 screens richer than that median.
Fair Value models
Bear ¥11.30Fair Value ¥11.59Bull ¥11.59
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (¥0.0293 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.20/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−17.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−8.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−7.0%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−3.1%
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−31.3%
Earnings growth per share plus dividend.
Earnings per share, growth per year−31.8%
Dividend (yield on the price)0.5%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.50% → 14%
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+44.8%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (China: IMF forecast 1.7% a year to 2030, 1.4% from 2016 to 2025) that is about +42.5% a year for the price.
Compare Liaoning Chengda Biotechnology Co. Ltd. A with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 651 stocks
Beats the industry median on 4/13 measures
Overall it trails its industry peers.
Valuation
Quality Score54 · Above median
Fair Value upside−45% · Below median
Profitability
Return on equity (TTM)1% · Above median
Return on assets0% · Above median
Net margin (TTM)4% · Below median
Operating margin (TTM)−1% · Below median
Growth and dividend
Revenue growth−24% · Bottom 25%
Dividend yield (TTM)0.5% · Bottom 25%
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/E (TTM)149.4× · Priciest 25%
P/B0.93× · Cheaper than median
P/S (TTM)6.68× · Pricier than median
P/FCF39.7× · Priciest 25%
EV/EBITDA28.0× · Pricier than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)0· sector 0
PAST (return on equity)2· sector 0
HEALTH (low debt)0· sector 97
DIVIDEND (yield)10· sector 23
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Liaoning Chengda Biotechnology Co. Ltd. A Fair Value". https://www.fairvalue-calculator.com/stock/688739
Frequently asked questions
Is Liaoning Chengda Biotechnology Co. Ltd. A (688739) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of ¥11.59 versus a price of ¥20.92, about −45% upside (overvalued).
What is the fair value of 688739?
Our model-based fair value for Liaoning Chengda Biotechnology Co. Ltd. A is ¥11.59 (as of Sep 23, 2026), built from audited fundamentals. The current price: ¥20.92.
What is the quality score of 688739?
Liaoning Chengda Biotechnology Co. Ltd. A has a Quality Score of 54/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Liaoning Chengda Biotechnology Co. Ltd. A (688739)?
Our model-based price target is the fair value of ¥11.59 (as of Sep 23, 2026) from 24 valuation models. Cautious scenario ¥11.30, optimistic scenario ¥11.59. It is a calculation from audited fundamentals, not an analyst target.
What is the Liaoning Chengda Biotechnology Co. Ltd. A stock forecast for 2026?
Our models put fair value at ¥11.59, about −45% upside versus a price of ¥20.92 (overvalued). Cautious scenario ¥11.30, optimistic scenario ¥11.59. The calculation is refreshed regularly with new filings.
What is the revenue of Liaoning Chengda Biotechnology Co. Ltd. A (688739)?
Liaoning Chengda Biotechnology Co. Ltd. A reported trailing-twelve-month revenue of about 1.3B CNY (latest available figure, as of Sep 23, 2026).
Does Liaoning Chengda Biotechnology Co. Ltd. A pay a dividend?
Liaoning Chengda Biotechnology Co. Ltd. A currently shows a dividend yield of about 0.48% relative to its recent price (as of Sep 23, 2026).
What growth is priced into Liaoning Chengda Biotechnology Co. Ltd. A (688739)?
For today's price to be fair in a discounted-cash-flow model, Liaoning Chengda Biotechnology Co. Ltd. A would have to grow free cash flow by +44.8 % per year for five years (discount rate 9.1 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -7.0 % per year. As of Sep 23, 2026.
What discount rate (WACC) does the fair value of 688739 use?
Our models discount Liaoning Chengda Biotechnology Co. Ltd. A at 9.1 %: a base by market capitalisation (mid), damped by beta 0.42, country premium for China. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Liaoning Chengda Biotechnology Co. Ltd. A that is +44.8 % per year a year over ten years, using the same discount rate (9.1 %) and the same formula as our fair value.
How much growth has Liaoning Chengda Biotechnology Co. Ltd. A (688739) delivered so far?
Over the past 5 years revenue at Liaoning Chengda Biotechnology Co. Ltd. A grew -7.0 % a year. The price currently implies +44.8 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Liaoning Chengda Biotechnology Co. Ltd. A (688739) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into Liaoning Chengda Biotechnology Co. Ltd. A (+44.8 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Liaoning Chengda Biotechnology Co. Ltd. A (688739)?
The free-cash-flow yield on the price is 0.38 %: that much free cash flow Liaoning Chengda Biotechnology Co. Ltd. A produces per unit of market value. When it exceeds the discount rate of our models (9.1 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Liaoning Chengda Biotechnology Co. Ltd. A (688739)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Liaoning Chengda Biotechnology Co. Ltd. A it is ¥11.59 per share (as of Sep 23, 2026), against a price of ¥20.92. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Liaoning Chengda Biotechnology Co. Ltd. A stock overvalued or undervalued in 2026?
As of Sep 23, 2026, 688739 trades above its calculated fair value: price ¥20.92, fair value ¥11.59, a gap of about −45% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 688739?
No. The price is what the market pays today (¥20.92); the fair value is what the company's own numbers justify (¥11.59). For Liaoning Chengda Biotechnology Co. Ltd. A the two are ¥9.33 per share apart. That gap is exactly why we show both numbers side by side.
How much is Liaoning Chengda Biotechnology Co. Ltd. A worth?
The market values Liaoning Chengda Biotechnology Co. Ltd. A at about 8.7B CNY (market capitalisation, as of Sep 23, 2026). Per share that is ¥20.92; our models calculate a fair value of ¥11.59 per share.
What do the bullish and bearish scenarios say about 688739?
Our models span a range for Liaoning Chengda Biotechnology Co. Ltd. A: cautious scenario ¥11.30, base ¥11.59, optimistic ¥11.59 per share (as of Sep 23, 2026, price ¥20.92). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 688739?
Liaoning Chengda Biotechnology Co. Ltd. A trades at a price-to-earnings ratio of 149.4 (as of Sep 23, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ¥11.59 is built from several models across several years. Other multiples: P/B 0.9, P/S 6.7, EV/EBITDA 28.0.
How solid is the balance sheet of Liaoning Chengda Biotechnology Co. Ltd. A (688739)?
Balance-sheet figures for Liaoning Chengda Biotechnology Co. Ltd. A (as of Sep 23, 2026): return on equity 0.6%. They feed the Quality Score of 54/100, which measures business quality independently of the share price.
How far is 688739 from its 52-week high?
Liaoning Chengda Biotechnology Co. Ltd. A trades at ¥20.92, about 25% below its 52-week high of ¥28.04 and 9% above the low of ¥19.13 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of ¥11.59 is for.
Which stocks are comparable to Liaoning Chengda Biotechnology Co. Ltd. A?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Liaoning Chengda Biotechnology Co. Ltd. A stock attractive at the current price?
The data as of Sep 23, 2026: price ¥20.92, calculated fair value ¥11.59 (−45%), Quality Score 54/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 688739 calculated?
We run Liaoning Chengda Biotechnology Co. Ltd. A through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ¥11.59, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Liaoning Chengda Biotechnology Co. Ltd. A itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Liaoning Chengda Biotechnology Co. Ltd. A (688739)?
The closing price on Sep 23, 2026 was ¥20.92. Our model-based fair value is ¥11.59, about −45% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Liaoning Chengda Biotechnology Co. Ltd. A right now?
The price sits above even our optimistic bull case (¥11.59). The favourable scenario is already priced in. Solid but not exceptional quality (54/100) and above fair value, neither a clear bargain nor a standout compounder. The models converge in a tight band (¥11.30 to ¥11.59), unusually little disagreement for a valuation.
Key figures of Liaoning Chengda Biotechnology Co. Ltd. A
How large is the market capitalisation of Liaoning Chengda Biotechnology Co. Ltd. A (688739)?
The market capitalisation of Liaoning Chengda Biotechnology Co. Ltd. A is 8.7B CNY (≈ $1.3B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Liaoning Chengda Biotechnology Co. Ltd. A (688739)?
The price-to-sales ratio of Liaoning Chengda Biotechnology Co. Ltd. A is 14.2 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Liaoning Chengda Biotechnology Co. Ltd. A (688739)?
Earnings per share at Liaoning Chengda Biotechnology Co. Ltd. A are ¥0.1400 (price ÷ EPS = P/E 149.4). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Liaoning Chengda Biotechnology Co. Ltd. A (688739)?
The dividend yield of Liaoning Chengda Biotechnology Co. Ltd. A is 0.5% (payout 71.4%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Liaoning Chengda Biotechnology Co. Ltd. A (688739)?
The net margin of Liaoning Chengda Biotechnology Co. Ltd. A is 9.5% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Liaoning Chengda Biotechnology Co. Ltd. A (688739)?
The return on equity (ROE) of Liaoning Chengda Biotechnology Co. Ltd. A is 0.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Liaoning Chengda Biotechnology Co. Ltd. A (688739)?
On an EBIT basis the return on assets of Liaoning Chengda Biotechnology Co. Ltd. A is 6.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Liaoning Chengda Biotechnology Co. Ltd. A (688739)?
The operating margin of Liaoning Chengda Biotechnology Co. Ltd. A is −0.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Liaoning Chengda Biotechnology Co. Ltd. A (688739)?
Revenue at Liaoning Chengda Biotechnology Co. Ltd. A is growing −23.7% versus a year earlier (3y avg −8.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Liaoning Chengda Biotechnology Co. Ltd. A (688739)?
Earnings per share at Liaoning Chengda Biotechnology Co. Ltd. A are growing −62.6% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed
Watch Liaoning Chengda Biotechnology Co. Ltd. A in the live analysis
One click puts Liaoning Chengda Biotechnology Co. Ltd. A on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
